Tempus AI, Inc. reported financial results for the quarter ended September 30, 2026, filing an -K with the SEC on November 2, 2026. The company reported total revenue of $411.5 million for the third quarter of 2026, representing a 23% increase compared to the same period in 2025.
Revenue was driven by two main segments. Diagnostics generated $303.5 million, a 20% increase, supported by oncology volume growth of 32%. The Data and Applications segment generated $108.1 million, a 33% increase, with Insights growing 29%.
On the balance sheet, Tempus ended the quarter with cash and marketable securities totaling $854.4 million. The company reported a net loss of $14.9 million for the quarter, which included $50.8 million in stock-based compensation expense and $42.8 million in unrealized gains on marketable securities. Adjusted EBITDA was reported at $25.6 million.
Tempus updated its full-year 2026 revenue guidance to $1.60 billion to $1.605 billion, representing approximately 25% growth. The company also expects full-year 2026 Adjusted EBITDA of approximately $65 million.
In operational news, Tempus announced a multi-year strategic collaboration with Merck and Moderna to support the commercialization of intismeran autogene, an individualized neoantigen therapy. Additionally, the company announced a collaboration with Bristol Myers Squibb (BMS) in October, bringing total data licensing bookings to over $550 million year-to-date.
Tempus also received regulatory clearance to continue its acquisition of Personalis, with a shareholder meeting scheduled for November 30, 2026.
